⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3649027 | 0.97 | — | — | |
| Sulfuric Acid SCHEMBL17422921 | 0.90 | MAOA (0.43) | — | |
| SCHEMBL21454436 | 0.87 | MAOA (0.50) | — | |
| Hydrochloric Acid SCHEMBL1027757 | 0.85 | MAOA (0.48) | — | |
| Trifluoroacetic Acid SCHEMBL23387488 | 0.84 | MAOA (0.35) | — | |
| Methacrylic Acid SCHEMBL1399534 | 0.84 | TDP1 (0.39) | — | |
| Acrylic Acid SCHEMBL1399454 | 0.84 | LMNA (0.42) | — | |
| SCHEMBL3259179 | 0.81 | — | — | |
| Propionamide SCHEMBL27866423 | 0.79 | TP53 (0.50) | — | |
| SCHEMBL821676 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 361 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117055311-A | Aqueous photoresist stripping liquid | 合肥中聚和成电子材料有限公司 | 2023-11-14 | — | — | CN | claimed |
| CN-107207442-A | Novel aryl-cyanoguanidine compounds | 拜耳医药股份有限公司 | 2017-09-26 | — | — | CN | claimed |
| CN-104784695-A | Method of using PI3K and MEK modulators | EXELIXIS INC | 2015-07-22 | — | — | CN | claimed |
| US-20110123434-A1 | COMBINATION THERAPIES COMPRISING QUINOXALINE INHIBITORS OF P13K-ALPHA FOR USE IN THE TREATMENT OF CANCER | EXELIXIS, INC (US) | 2011-05-26 | — | — | US | claimed |
| EP-1482912-B1 | NALTREXONE HYDROCHLORIDE COMPOSITIONS | EURO CELTIQUE SA (LU) | 2011-05-25 | — | — | EP | claimed |
| JP-4683842-B2 | — | — | 2011-05-18 | — | — | JP | claimed |
| US-20100087440-A1 | Phosphatidylinositol 3-Kinase Inhibitors and Methods of Their Use | EXELIXIS, INC. | 2010-04-08 | — | — | US | claimed |
| EP-2139483-A2 | COMBINATION THERAPIES COMPRISING QUINOXALINE INHIBITORS OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER | Exelixis, Inc. (US) | 2010-01-06 | — | — | EP | claimed |
| CN-101528231-A | Use of PI3K and MEK modulators in the treatment of cancer | EXELIXIS INC (US) | 2009-09-09 | — | — | CN | claimed |
| WO-2008127594-A2 | COMBINATION THERAPIES COMPRISING QUINOXALINE INHIBITORS OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER | EXELIXIS, INC. (US) | 2008-10-23 | — | — | WO | claimed |
| EP-1465892-A1 | GLYCINAMIDES AS FACTOR XA INHIBITORS | Bristol-Myers Squibb Company (US) | 2004-10-13 | — | — | EP | claimed |
| WO-2004060890-A1 | 2-OXOPYRIDIN-3-YL THIA (DI) AZOLE DERIVATES FOR USE IN THE TREATMENT OF CELL PROLIFERATION AND APOPTOSIS RELATED DISEASES | AMGEN INC. (US) | 2004-07-22 | — | — | WO | claimed |
| WO-2004045523-A2 | COMBINATION ADMINISTRATION OF AN INDOLINONE WITH A CHEMOTHERAPEUTIC AGENT FOR CELL PROLIFERATION DISORDERS | SUGEN, INC. (US) | 2004-06-03 | — | — | WO | claimed |
| WO-2004007457-A2 | SUBSTITUTED BENZYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2004-01-22 | — | — | WO | claimed |
| WO-2003077867-A2 | NALTREXONE HYDROCHLORIDE COMPOSITIONS | EURO-CELTIQUE, S.A. (LU) | 2003-09-25 | — | — | WO | claimed |
| WO-2003048158-A1 | GLYCINAMIDES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-06-12 | — | — | WO | claimed |
| EP-0790986-B1 | ANILINE DERIVATIVES | ZENECA LTD (GB) | 1999-01-20 | — | — | EP | claimed |
| US-5821246-A | USEFUL AS TYROSINE KINASE INHIBITORS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER | ZENECA LIMITED (GB) | 1998-10-13 | — | — | US | claimed |
| EP-0790986-A1 | ANILINE DERIVATIVES | ZENECA LIMITED (GB) | 1997-08-27 | — | — | EP | claimed |
| WO-1996015118-A1 | ANILINE DERIVATIVES | ZENECA LIMITED (GB) | 1996-05-23 | — | — | WO | claimed |